Valeant Q4 loss loss grows, sales fall 13% but adjusted earnings above estimates

Valeant posts bigger Q4 loss, revenue down 13%

LAVAL, Que. — Valeant Pharmaceuticals International Inc  (TSX:VRX) says its fourth quarter loss grew to US$515 million as the drug company’s revenue fell 13 per cent compared with the same period in 2015.

The Montreal-area company’s net loss, reported in U.S. currency, was equal to $1.47 per share while revenue was $2.4 billion, down $355 million from a year earlier.

In the fourth quarter of 2015, Valeant had a net loss of $385 million or $1.12 per share, and $2.76 billion of revenue.

The company, based in Laval, Que., said the increased net loss was due to a combination of factors including higher interest expenses and a bigger foreign exchange loss.

After adjustments, Valeant says, the company earned $441 million or $1.26 per share, down from $542 million or $1.55 per share in the fourth quarter of 2015. 

Adjusted earnings beat analyst estimates of $1.20 per share, according to Thomson Reuters data.

Based in Laval, Que., Valeant is Canada’s largest publicly traded pharmaceutical company. In addition to making a wide variety of drugs and medical devices, it owns the Bausche & Lomb contact lens business.

The Canadian Press

Note to readers: This is a corrected story. An earlier version misspelled Bausch.

Canadian Press

We are experiencing technical difficulties with our commenting platform and hope to be up and running again soon. In the meantime, you can still send us your thoughts on Facebook or Twitter, or submit a letter to the editor.